Journal of Antivirals & Antiretrovirals, vol.13, no.18, 2021 (Peer-Reviewed Journal)
Background: It is necessary to use an effective vaccine to end the COVID-19 pandemic. CoronaVac vaccine is used
in our country and we aimed to examine the level of antibody development after the first dose.
Methods: This is a retrospective, cross-sectional research. The data of the people, who applied to a university hospital
between January and February 2021,were analyzed. Those who had SARS-CoV-2 IgG and IgM measurement in
the previous two weeks before the CoronoVac vaccine, and those who were both found negative and who had
SARS-CoV-2 IgG and IgM measurement after the first dose of CoronaVac vaccine were included in the research.
SARS-CoV-2 IgG/IgM were measured by VIDAS® (BioMérieux, Marcy-l'Etoile, France) device for the detection of
spike protein specific IgG/IgM of SARS-CoV-2 in human serum with ELFA (Enzyme Linked Fluorescent Assay)
Results: 30 people were included in this research. It was found that the individuals had SARS-CoV-2 IgG and IgM
measurements between 14 and 21 days after the first dose of CoronaVac vaccine. It was observed that 30% (n=9)
of the cases had a history of COVID-19.The rate of positivity for SARS CoV-2 IgG level after vaccination was 40%
(n=12/30) and it was 77.8% (n=7/9) in cases with a history of COVID-19 and it was significantly higher than those
without a history of COVID-19 (p=0.013).
Conclusions: A single dose of CoronaVac vaccine is not enough, but perhaps a single dose of vaccination may be
sufficient for those who have had COVID-19.
Keywords: COVID-19; CoronaVac vaccine; SARS-CoV-2 IgG